TScan Therapeutics Inc. (TCRX)
TScan Therapeutics Inc. (TCRX) Stock Price, Analysis & Data
| Bid | 0.54 |
| Market Cap | 49.67M |
| Revenue (ttm) | 9.14M |
| Net Income (ttm) | -124.31M |
| Beta | 1.07 |
| EPS (ttm) | -0.96 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.86 |
| P/B (ttm) | 0.47 |
| P/S (ttm) | 5.44 |
| Earnings Date | Nov 12, 2025 |
| Ask | 0.97 |
| Volume | 141,530 |
| Avg. Volume (20D) | 643,475 |
| Open | 0.79 |
| Previous Close | 0.78 |
| Day's Range | 0.75 - 0.79 |
| 52-Week Range | 0.72 - 2.57 |
| Analyst | Strong Buy |
| Price Target | 6 (689.47%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is...
Financial Performance
In 2025, TScan Therapeutics's revenue was 10.32M, an increase of 266.65% compared to the previous year's 2.82M. Earnings were -129.77M, an increase of 1.78%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for TCRX stock is "Strong Buy". The 12-month stock price forecast is 6, which is upside of 689.47% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
